COVID-19 in unvaccinated patients with inborn errors of immunity-polish experience.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 26 05 2022
accepted: 07 09 2022
entrez: 10 10 2022
pubmed: 11 10 2022
medline: 12 10 2022
Statut: epublish

Résumé

At the beginning of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic, patients with inborn errors of immunity (IEI) appeared to be particularly vulnerable to a severe course of the disease. It quickly turned out that only some IEI groups are associated with a high risk of severe infection. However, data on the course of Coronavirus Disease 2019 (COVID-19) in patients with IEI are still insufficient, especially in children; hence, further analyses are required. The retrospective study included 155 unvaccinated people with IEI: 105 children and 50 adults (67.7% and 32.3%, respectively). Male patients dominated in the study group (94 people, 60.6%). At least two comorbidities were found in 50 patients (32.3%), significantly more often in adults (56% vs. 21%). Adult patients presented significantly more COVID-19 symptoms. Asymptomatic and mildly symptomatic course of COVID-19 was demonstrated in 74.8% of the entire group, significantly more often in children (88.6% vs. 46%). Moderate and severe courses dominated in adults (54% vs. 11.4%). Systemic antibiotic therapy was used the most frequently, especially in adults (60% vs. 14.3%). COVID-19-specific therapy was used almost exclusively in adults. In the whole group, complications occurred in 14.2% of patients, significantly more often in adults (30% vs. 6.7%). In the pediatric group, there were two cases (1.9%) of multisystem inflammatory syndrome in children. Deaths were reported only in the adult population and accounted for 3.9% of the entire study group. The death rate for all adults was 12%, 15.4% for adults diagnosed with common variable immunodeficiency, 12.5% for those with X-linked agammaglobulinemia, and 21.4% for patients with comorbidity. The results of our study imply that vaccinations against COVID-19 should be recommended both for children and adults with IEI. Postexposure prophylaxis and early antiviral and anti-SARS-CoV-2 antibody-based therapies should be considered in adults with IEI, especially in those with severe humoral immune deficiencies and comorbidity.

Identifiants

pubmed: 36211407
doi: 10.3389/fimmu.2022.953700
pmc: PMC9537609
doi:

Substances chimiques

Anti-Bacterial Agents 0
Antiviral Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

953700

Informations de copyright

Copyright © 2022 Kołtan, Ziętkiewicz, Grześk, Becht, Berdej-Szczot, Cienkusz, Ewertowska, Heropolitańska-Pliszka, Krysiak, Lewandowicz-Uszyńska, Mach-Tomalska, Matyja-Bednarczyk, Milchert, Napiórkowska-Baran, Pieniawska-Śmiech, Pituch-Noworolska, Renke, Roliński, Rywczak, Stelmach-Gołdyś, Strach, Suchanek, Sulicka-Grodzicka, Szczawińska-Popłonyk, Tokarski, Więsik-Szewczyk, Wolska-Kuśnierz, Zeman and Pac.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Allergy Clin Immunol. 2020 Jul;146(1):211-213.e4
pubmed: 32333914
Pediatr Allergy Immunol. 2022 Jan;33(1):e13661
pubmed: 34510555
Front Immunol. 2022 Jan 31;13:837243
pubmed: 35173743
Clin Immunol. 2021 Sep;230:108821
pubmed: 34391937
JAMA Netw Open. 2021 Jun 1;4(6):e2116420
pubmed: 34110391
Curr Opin Pediatr. 2021 Dec 1;33(6):648-656
pubmed: 34734915
Clin Exp Immunol. 2022 Sep 29;209(3):247-258
pubmed: 35641155
J Clin Immunol. 2018 Oct;38(7):816-832
pubmed: 30302726
J Clin Immunol. 2021 Feb;41(2):345-355
pubmed: 33263173
J Clin Immunol. 2021 Oct;41(7):1515-1522
pubmed: 34231093
Front Immunol. 2019 Jul 19;10:1272
pubmed: 31379802
Am J Clin Exp Immunol. 2021 Oct 15;10(3):77-85
pubmed: 34824897
J Clin Immunol. 2021 Oct;41(7):1479-1489
pubmed: 34164762
Clin Exp Immunol. 2015 Oct;182(1):45-50
pubmed: 26031847
J Clin Invest. 2021 Jul 15;131(14):
pubmed: 34061775
Front Immunol. 2022 Feb 28;13:835770
pubmed: 35296097
J Allergy Clin Immunol Pract. 2021 Jan;9(1):504-507.e1
pubmed: 33217615
Expert Rev Clin Immunol. 2021 Feb;17(2):163-168
pubmed: 33412960
J Clin Med. 2021 Oct 30;10(21):
pubmed: 34768630
J Allergy Clin Immunol. 2021 Feb;147(2):520-531
pubmed: 32980424
Am J Med Sci. 2020 Dec;360(6):740-741
pubmed: 32773108
J Med Virol. 2021 Mar;93(3):1449-1458
pubmed: 32790106
J Clin Immunol. 2021 Oct;41(7):1463-1478
pubmed: 34114122

Auteurs

Sylwia Kołtan (S)

Department of Pediatrics, Hematology and Oncology, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Toruń, Bydgoszcz, Poland.

Marcin Ziętkiewicz (M)

Department of Internal Medicine, Connective Tissue Diseases and Geriatrics, Medical University of Gdansk, Gdansk, Poland.

Elżbieta Grześk (E)

Department of Pediatrics, Hematology and Oncology, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Toruń, Bydgoszcz, Poland.

Rafał Becht (R)

Clinical Department of Oncology, Chemotherapy and Cancer Immunotherapy, Pomeranian Medical University in Szczecin, Szczecin, Poland.

Elżbieta Berdej-Szczot (E)

Department of Paediatric and Paediatric Endocrinology, Upper-Silesian Paediatric Health Center, Katowice, Poland.

Magdalena Cienkusz (M)

Department of Paediatric Haematology and Oncology and Transplantology Medical University of Lublin, Lublin, Poland.

Marlena Ewertowska (M)

Department of Pediatrics, Hematology and Oncology, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Toruń, Bydgoszcz, Poland.

Edyta Heropolitańska-Pliszka (E)

Department of Immunology, Children's Memorial Health Institute, Warsaw, Poland.

Natalia Krysiak (N)

Department of Pediatrics, Immunology and Nephrology, Institute of Polish Mother's Health Center, Łódź, Poland.

Aleksandra Lewandowicz-Uszyńska (A)

3rd Department and Clinic of Paediatrics, Immunology and Rheumatology of Developmental Age, Wroclaw Medical University, Wroclaw, Poland.
Department of Clinical Immunology and Paediatrics, Provincial Hospital J. Gromkowski, Wroclaw, Poland.

Monika Mach-Tomalska (M)

Department of Immunology, University Children's Hospital of Cracow, Cracow, Poland.

Aleksandra Matyja-Bednarczyk (A)

2nd Department of Internal Medicine, Jagiellonian University Medical College, Krakow, Poland.

Marcin Milchert (M)

Department of Internal Medicine Rheumatology Diabetology Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland.

Katarzyna Napiórkowska-Baran (K)

Department and Clinic of Allergology, Clinical Immunology and Internal Diseases, Ludwik Rydygier Collegium Medicum in Bydgoszcz Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland.

Karolina Pieniawska-Śmiech (K)

Department of Clinical Immunology and Paediatrics, Provincial Hospital J. Gromkowski, Wroclaw, Poland.
Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.

Anna Pituch-Noworolska (A)

Department of Immunology, University Children's Hospital of Cracow, Cracow, Poland.

Joanna Renke (J)

Department of Pediatrics, Hematology and Oncology, Medical University of Gdańsk, Gdańsk, Poland.

Jacek Roliński (J)

Department of Clinical Immunology, Medical University of Lublin, Lublin, Poland.

Iwona Rywczak (I)

Department of Immunology, University Children's Hospital of Cracow, Cracow, Poland.

Agnieszka Stelmach-Gołdyś (A)

Department of Hematology, Holycross Cancer Center, Kielce, Poland.
Department of Immunology, Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland.

Magdalena Strach (M)

Department of Rheumatology and Immunology, Jagiellonian University Collegium Medicum, Kraków, Poland.

Hanna Suchanek (H)

Department of Internal Medicine, Connective Tissue Diseases and Geriatrics, Medical University of Gdansk, Gdansk, Poland.

Joanna Sulicka-Grodzicka (J)

Department of Rheumatology and Immunology, Jagiellonian University Collegium Medicum, Kraków, Poland.

Aleksandra Szczawińska-Popłonyk (A)

Department of Pediatric Pneumonology, Allergy and Clinical Immunology, Institute of Pediatrics, Poznań University of Medical Sciences, Poznań, Poland.

Sławomir Tokarski (S)

Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland.

Ewa Więsik-Szewczyk (E)

Department of Internal Medicine, Pneumonology, Allergology and Clinical Immunology, Central Clinical Hospital of the Ministry of National Defense, Military Institute of Medicine, Warsaw, Poland.

Beata Wolska-Kuśnierz (B)

Department of Immunology, Children's Memorial Health Institute, Warsaw, Poland.

Krzysztof Zeman (K)

Department of Pediatrics, Immunology and Nephrology, Institute of Polish Mother's Health Center, Łódź, Poland.

Małgorzata Pac (M)

Department of Immunology, Children's Memorial Health Institute, Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH